A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24

2024-510774-24-00 Human pharmacology (Phase I) - Other Ended

Start 25 Mar 2024 · End 7 May 2024 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 30
Countries 1
Sites 1

healthy male subjects

Key facts

Sponsor
Adamed Pharma S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Male Urogenital Diseases [C12]
Trial duration
25 Mar 2024 → 7 May 2024
Decision date (initial)
2024-03-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

healthy male subjects

VersionLevelCodeTermSystem organ class
21.1 PT 10004446 Benign prostatic hyperplasia 100000004872

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Adamed Pharma S.A.

Sponsor organisation
Adamed Pharma S.A.
Address
Ul. Mariana Adamkiewicza 6a, Pienkow Pienkow
City
Czosnow
Postcode
05-152
Country
Poland

Scientific contact point

Organisation
Adamed Pharma S.A.
Contact name
Pharmacokinetic Study Team

Public contact point

Organisation
Adamed Pharma S.A.
Contact name
Pharmacokinetic Study Team

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 30 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Cepha s.r.o.
clinic, Komenskeho 19, Severni Predmesti, Plzen 1

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-03-25 2024-05-07 2024-03-25

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 1 file

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

TypeTitleVersion
Clinical study report (for publication) Clinical Study Report 557_Final_redacted 1

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-15 Czechia Acceptable
2024-03-08
2024-03-11
2 NON SUBSTANTIAL MODIFICATION NSM-2 2024-03-12 Czechia Acceptable
2024-03-08
2024-03-12